Minimally invasive surgery for perihilar cholangiocarcinoma reduces blood loss and hospital stay but increases operative time
Robotic and laparoscopic surgery show mixed results for bile duct cancer
This systematic review and meta-analysis of 24 studies involving 1,598 patients compared laparoscopic surgery (LS) and robot-assisted surger…
Minimally invasive surgeries for bile duct cancer can reduce blood loss and hospital stays, but they do not improve long-term survival rates…
Systematic review and meta-analysis on neoadjuvant selection and liver transplantation for perihilar cholangiocarcinoma
Transplant selection may boost survival in bile duct cancer
This systematic review and meta-analysis synthesized evidence on protocol-based neoadjuvant selection and liver transplantation versus liver…
For a tough bile duct cancer, a new approach to choosing patients for transplant shows better long-term survival than surgery alone.
Research across Intrahepatic Cholangiocarcinoma
Related studies from across the Intrahepatic Cholangiocarcinoma family.
RTK-RAS pathway alterations are more frequent in cholangiocarcinoma than in hepatocellular carcinoma
Genetic markers help distinguish between different types of liver and bile duct cancers
This meta-analysis of genomic and single-cell transcriptomic data identifies a higher burden of RTK-RAS alterations in cholangiocarcinoma co…
New research identifies specific genetic signals that help doctors tell the difference between two similar types of liver cancer.
Preoperative radiological evaluation identifies portal annular pancreas and aberrant hepatic artery in cholangiocarcinoma surgery
Surgery Success for Complex Liver and Pancreas Anatomy
This case report describes a successful pancreaticoduodenectomy in a 55-year-old male with obstructive jaundice and a portal annular pancrea…
A successful surgery on a patient with a rare pancreatic condition highlights the importance of detailed imaging for complex anatomical issu…
High CALLY index correlates with improved survival in hepatobiliary and pancreatic malignancies
High CALLY index linked to better survival in liver and pancreatic cancers
This meta-analysis of 3833 patients found that a high C-reactive protein-albumin-lymphocyte (CALLY) index is associated with significantly b…
A high CALLY score may signal better survival outcomes for patients with liver, bile duct, and pancreatic cancers.
Minimally invasive pancreaticoduodenectomy reduces blood loss and hospital stay in distal cholangiocarcinoma surgery
Minimally invasive surgery shows benefits for certain bile duct cancer
This meta-analysis of retrospective cohort studies evaluates minimally invasive pancreaticoduodenectomy (MIPD) compared to open pancreaticod…
Minimally invasive surgery can reduce blood loss and hospital stays for patients undergoing surgery for distal cholangiocarcinoma.
Migrated pancreaticojejunal stents may act as chronic local irritants potentially linked to metachronous cholangiocarcinoma
Migrated Surgical Stent Linked to Late Cancer Diagnosis
This case report describes a 62-year-old male with metachronous hilar cholangiocarcinoma and an intraoperatively migrated pancreaticojejunal…
A single case report suggests that an old, migrated surgical stent may act as a local irritant leading to cancer.
Narrative review on KMT2C alterations in gastrointestinal cancers and therapeutic implications
Genetic changes in gut cancers may open new treatment doors for patients
This narrative review synthesizes evidence on KMT2C alterations across gastrointestinal malignancies. It links KMT2C dysfunction to transcri…
A review of genetic changes in gastrointestinal cancers suggests new ways to treat tumors by targeting specific DNA repair weaknesses.
Narrative review discusses cellular immunotherapy strategies for cholangiocarcinoma with noted limitations
New CAR T Cell Strategy May Beat Tough Liver Cancer
This narrative review examines cellular immunotherapy approaches for cholangiocarcinoma, including CAR-based therapies, multi-antigen design…
A new plan to fight bile duct cancer combines advanced cell therapy with other drugs to break through tumor defenses.
Lirafugratinib sequencing with futibatinib shows feasibility in FGFR2-driven cancers based on early-phase trial data
Can a new cancer drug work better if you switch to another drug after it stops?
This Phase I/II preprint trial evaluated lirafugratinib in 30 patients with FGFR2-driven cancers, including intrahepatic cholangiocarcinoma.
When a cancer drug stops working, switching to a different one might help because the two medicines attack the disease in slightly different…
Meta-analysis of GEO datasets identifies specific gene expression alterations in aflatoxin-associated intrahepatic cholangiocarcinoma
Could aflatoxin exposure change specific genes in liver cancer, and what does that mean for prevention?
This meta-analysis examined genomic data from five Gene Expression Omnibus datasets to identify expression patterns in aflatoxin-induced int…
Liver cancer linked to aflatoxin exposure changes six specific genes, revealing new genetic pathways that could help doctors find early warn…